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Abstract
Background: Ischaemic heart disease and congestive heart failure are common and important
conditions in family practice. Effective treatments may be underutilized, particularly in women and
the elderly. The objective of the study was to determine the rate of prescribing of evidence-based
cardiovascular medications and determine if these differed by patient age or sex.
Methods: We conducted a two-year cross-sectional study involving all hospitals in the province
of Nova Scotia, Canada. Subjects were all patients admitted with ischaemic heart disease with or
without congestive heart failure between 15 October 1997 and 14 October 1999. The main
measure was the previous outpatient use of recommended medications. Chi-square analyses
followed by multivariate logistic regression analyses were used to examine age-sex differences.
Results: Usage of recommended medications varied from approximately 60% for beta-blockers
and angiotensin converting enzyme (ACE) inhibitors to 90% for antihypertensive agents. Patients
aged 75 and over were significantly less likely than younger patients to be taking any of the
medication classes. Following adjustment for age, there were no significant differences in
medication use by sex except among women aged 75 and older who were more likely to be taking
beta-blockers than men in the same age group.
Conclusions:  The use of evidence-based cardiovascular medications is rising and perhaps
approaching reasonable levels for some drug classes. Family physicians should ensure that all eligible
patients (prior myocardial infarction, congestive failure) are offered beta-blockers or ACE
inhibitors.
Background
Ischaemic heart disease (IHD) and congestive heart failure
(CHF) are conditions commonly encountered in primary
care, and optimal management by family physicians (FPs)
in concert with other health care providers should
increase the chance of an optimal patient outcome. In
recent years, the ability of FPs to enhance their patients'
outcomes has increased markedly, with large randomized
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controlled trials demonstrating the value in patients with
IHD of beta blocking agents (BBs), antithrombotic agents
and antilipemic agents, and angiotensin converting
enzyme (ACE) inhibitors in patients who also have mod-
erate to severe left ventricular dysfunction. This evidence
was summarized, and the benefit of treating hypertension
in patients with IHD to target levels was reaffirmed, in five
recommendations included in a 1997 consensus state-
ment for Canadian physicians [1].
A PubMed search for utilization of those drug groups in
Canada revealed few articles about ambulatory patients.
In 1993–1995, BBs were dispensed to 51.4% of patients
in the year following a myocardial infarction (MI) in
Ontario, and significantly fewer to women and older
patients [2]. Another study in Ontario revealed that older
age was associated with a greater likelihood of receiving a
dose lower than evaluated in trials, although there was no
difference by sex in this study [3]. Acetylsalicylic acid
(ASA) was used by 55% of patients post-MI in Nova Scotia
in 1995 [4]. With respect to the management of hyperten-
sion in Canada, data from the Canadian Heart Health Sur-
vey (n = 23,129) gathered from 1986 to 1992 have been
used to estimate that 1,326,811 (66%) patients are treated
out of 1,997,866 who are aware of their diagnosis [5].
While complete and accurate data on appropriate use of
medications in ambulatory patients are not yet available
in Nova Scotia, a reasonable perspective may be gained
through the use of information collected from patients on
admission to hospital regarding drugs being taken for pre-
existing conditions. The availability of a database for a
large population-based study of cardiovascular disease,
Improving Cardiovascular Outcomes in Nova Scotia
(ICONS) [6], gave us the opportunity to elicit this infor-
mation. Our objectives were to determine the rate of pre-
scribing of evidence-based cardiovascular therapies and
determine if these differed by patient age or sex. Specifi-
cally, we investigated the proportion of patients with IHD
taking an antithrombotic agent, post-MI patients taking a
BB, IHD patients with hyperlipidemia taking a lipid low-
ering agent, IHD patients with hypertension taking a drug
with antihypertensive properties, and IHD patients with
CHF taking an ACE inhibitor.
Methods
All patients admitted to hospital with IHD (unstable
angina or acute myocardial infarction), CHF, or atrial
fibrillation in Nova Scotia in the two-year period between
15 October 1997 and 14 October 1999 were included in
the ICONS database. This study has included only those
patients with IHD, with or without CHF, admitted for
either diagnosis. These diagnoses were not confirmed
with investigative measures, such as catheterization stud-
ies or left ventricular function measures. The procedures
used to ensure a high sensitivity for identifying all eligible
patients, and the data quality management measures that
ensured a 95% or higher data accuracy of chart abstrac-
tion, have been previously reported [6]. All pertinent
inpatient charts were abstracted by trained nurses and
health record professionals for specific data elements such
as history of previous illnesses and drugs taken, physical
examination findings, investigations, and interventions.
All parts of the chart were reviewed. All data were entered
directly into a computer and downloaded daily to the
project registry. Our study measures were age, sex, prior
patient conditions or diagnoses as recorded in the hospi-
tal chart (IHD, MI, CHF, hyperlipidemia, hypertension),
and the drugs that patients were taking prior to admission,
also as recorded in the hospital chart. Drugs were classi-
fied and aggregated using the World Health Organization
Anatomical Therapeutic Chemical classification system
[7]. Details are available on request. Angiotensin receptor
blockers (ARBs) were included with ACE inhibitors
because many clinicians use them in patients intolerant of
ACE inhibitors and evidence is suggestive that at least val-
sartan conveys a similar benefit [8]. Both warfarin and
antiplatelet agents reduce the risk of another MI [9] and so
have been included in a group generically termed anti-
thrombotic agents.
This study used a two-year cross-sectional design. It exam-
ined the drug use and prior diagnoses by age and sex in
patients enrolled in the ongoing ICONS cohort study. For
each diagnostic group (IHD, post-MI, IHD with hyperlip-
idemia, IHD with hypertension, and IHD with CHF), chi-
square analyses followed by multivariate logistic regres-
sion analyses were used to examine the age-sex differences
in the use of the recommended evidence-based medica-
tion. The main effects of age and sex were examined in
addition to the interaction of both variables. All analyses
were conducted using SAS software [10]. The Queen Eliz-
abeth II Health Sciences Center Research Ethics Commit-
tee approved the ICONS study protocol.
Results
During the two-year study period, a total of 6,805 patients
were admitted to hospital in Nova Scotia with IHD with
or without CHF and were included in the ICONS data-
base. The majority of patients were male (62%) and
younger than 75 years of age (62.9%). Table 1 summa-
rizes the number of patients by sex and age for each diag-
nostic group along with the evidence-based treatment
recommendation from the 1997 consensus statement on
the evaluation and management of chronic IHD [1].
Figure 1 illustrates the proportion of patients treated
according to the recommendation by age group and asso-
ciated significant p-values derived using chi-square analy-
sis. Proportions varied from a low of approximately 60%BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/6
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Table 1: Patient demographics by diagnostic group
Previous 
Diagnosis
Recommended Rx No. of patients Males No. (%) Females No. (%) Age ≤ 74 No. (%) Age ≥ 75 No. (%)
IHD Antithrombotic (Grade A*, Class I**) 6805 4217 (62.0) 2588 (38.0) 4281 (62.9) 2524 (37.1)
MI Beta-blocker (Grade A, Class I) 5526 3509 (63.5) 2017 (36.5) 3398 (61.5) 2128 (38.5)
IHD + 
hyperlipidemia
Lipid-lowering agent (Grade A, Class II***) 3210 2071 (64.5) 1139 (35.5) 2573 (80.2) 637 (19.8)
IHD + hypertension Antihypertensive agent (Grade A, Class I) 3594 2046 (56.9) 1548 (43.1) 2205 (61.4) 1389 (38.6)
IHD + CHF ACEI (Grade A, Class I) 3490 1695 (48.6) 1795 (51.4) 1361 (39.0) 2129 (61.0)
* Grade A: Evidence sufficient for universal use ** Class I: Evidence based on at least one prospective randomized controlled trial *** Class II: 
Evidence based on at least one nonrandomized cohort comparison or multicentred case studies, chronological series or extraordinary results from 
nonrandomized trials.
Proportion of patients taking recommended medications, by age Figure 1
Proportion of patients taking recommended medications, by age
(1) In patients with prior IHD (n=6805)
(2) In patients with prior MI (n=5526)
(3) In patients with prior IHD and hyperlipidemia (n=3210)
(4) In patients with prior IHD and hypertension (n=3594)
(5) In patients with prior IHD and CHF (n=3490)
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for BBs in patients post-MI and ACE inhibitors in patients
with IHD and CHF, to approximately 90% for antihyper-
tensive agents in patients with IHD and hypertension.
Within each diagnostic group, age was significantly asso-
ciated with recommended treatment usage at the .05 level
of significance. After accounting for sex, patients aged 75
years and over were significantly less likely than younger
patients to be taking 1) any antithrombotic agent in
patients with previous IHD (odds ratio [OR] 0.69; 95%
confidence interval [CI] 0.61–0.78), 2) BBs post-MI (OR
0.60; 95% CI 0.54–0.68), 3) antilipemic agents among
those with IHD and hyperlipidemia (OR 0.74; 95% CI
0.61 – 0.89), 4) any antihypertensive agent in patients
with IHD and hypertension (OR 0.71; 95% CI 0.54–0.93)
or 5) ACE inhibitors/ARBs in those with previous IHD
and CHF (OR 0.77; 95% CI 0.67–0.89).
Examination of the crude proportion of males and
females who received each medication does not point to
major differences (Figure 2). Chi-square tests for associa-
tion indicate a significant difference between males and
females in medication use only among patients with pre-
vious IHD taking any antithrombotic agent (p = 0.001).
However, following adjustments for age, this association
was no longer evident. Further investigation revealed that
elderly females (those aged 75 and older) with previous
MI tended to have a greater likelihood of taking BBs than
elderly males (OR 1.31; 95% CI 1.10–1.55). No other sig-
nificant differences in recommended medication use
within diagnostic groups were evident by sex.
Discussion
Rapid changes in cardiovascular therapies will mean that
data from retrospective studies will frequently lag behind
published evidence. Our results indicated a trend toward
compliance with evidence-based therapies, consistent
with other studies [11-13]. Use of anti-thrombotic and
antilipemic medication was much higher than had been
reported in previous Canadian and American
data,[4,14,15] perhaps close to reasonable targets given
contraindications and patient freedom to decline treat-
ment. The higher proportion of eligible patients on antili-
pemic medications was consistent with the reported
increase in statin use following publication of major trials
[16,17].
The use of drugs with antihypertensive properties in
patients with prior hypertension was very high (over
90%), despite it being an asymptomatic condition. This is
similar to the 92% reported in the VALUE trial baseline
data.[18] Other studies of the use of antihypertensive
medications have yielded a wide variation in proportions
treated: 30% of men and 43% of women in Germany [19]
in pooled data from 1989/90 and 1994/95; 39% of men
and 55% of women in South Africa [20] in 1998; 53% of
Hispanic adults, 64% of whites, and 73% of blacks in an
American study [21] of data from 1992; and 80% in Bel-
gium [22] in 2000. Perhaps the higher proportions gener-
ally seen in more recent studies indicate that both patients
and physicians were more accepting of the value of anti-
hypertensive medications in the late 1990's than they
were a decade previously.[5] Additionally, patients in our
study also had IHD and might be expected to make more
frequent visits to the physician and have more attention
paid to their BP and any necessary treatment. However,
because of an overlap in indications for many drugs (e.g.,
BBs, ACE inhibitors, calcium channel blockers can be
used to treat IHD or hypertension), it is not possible to
establish with certainty that hypertension was the primary
reason for treatment with these medications or that
patients received an antihypertensive regimen that ade-
quately controlled blood pressure.
In contrast, BB use post-MI was slightly higher than previ-
ous reports,[2,23] perhaps because our data were col-
lected approximately 5 years later. ACE inhibitor use in
IHD patients with CHF was also marginally higher, at
approximately 60%. It is unclear what impact comorbidi-
ties, side effects, and patient refusal may have had on
compliance. Some of the barriers to use of both of these
drug groups can be found in a recent report from an Eng-
lish study [24]. The evidence supporting the value of both
classes of medications is strong and plentiful [1]; given the
cumulative impact of evidence over time [25], we doubt
that lack of awareness by physicians is a major issue. Fur-
ther research with patients who appear eligible for BBs or
ACE inhibitors but are untreated is needed to clarify the
reasons for this care gap and suggest strategies to optimize
management.
Lower treatment levels for patients 75 and older were con-
sistent with patterns reported in other studies [2,26-30].
This may reflect a variety of factors, including less con-
vincing evidence for the safety and efficacy of medications
for secondary prevention in the 75 and older age group
[31], comorbidities, and physician attitudes towards
treating the elderly. Although our data showed that antili-
pemic utilization was lower for the elderly group (68.3%)
than for those under 75 years of age (75%), it was still
higher than the 59.4% reported for the 65–75 age group
in a recent American study [32]. This may be due to the
public drug insurance for most seniors in Nova Scotia
(Seniors' Pharmacare) in contrast to greater out-of-pocket
costs in the United States. Future research is needed to
identify the factors associated with differing utilization in
the elderly.
In contrast to the findings of others [2,17,19,29,30,33],
after adjustment for age we did not find sex differences in
drug use except for BBs. Women aged 75 and older wereBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/6
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found to use BBs more than men in the same age group.
However, the literature provides other examples of studies
in which differences by sex were absent or minimal. A
recently published study [34] of post- myocardial infarc-
tion patients reported no significant differences by sex for
ACE inhibitors, BBs, ASA and anticoagulants other than
ASA, but the proportion of men taking antilipemic agents
remained higher after adjustment for age. Weiss reported
no differences between men and women in hypertension
treatment [35], and Rochon found no difference in low-
dose BB therapy by sex [3]. We cannot explain these vari-
ations; perhaps physicians are increasingly recognizing
the importance of cardiovascular disease in women and
applying the evidence to them equitably.
Despite the advantage of drawing on population-based,
detailed clinical data abstracted from the medical record,
our data have several limitations. Only patients who were
hospitalized for a cardiovascular (CV) diagnosis in the
two-year period were included, and they were presumably
sicker than the usual ambulatory patient. We had no reli-
able data on allergies, previous adverse drug reactions or
contraindications to medications and, therefore, there
may have been legitimate reasons why some patients were
not receiving recommended medications. The relevance
Proportion of patients taking recommended medications, by sex Figure 2
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for the ICONS study of non-documentation of important
clinical information in the hospital record has been
described in detail in another paper [36], and we acknowl-
edge that inaccurate self-reporting of diagnostic and drug
information by patients could have contributed to that.
For our subset of patients, non-documentation was 22.9%
regarding presence or absence of hypertension, and
33.7% for hyperlipidemia. We do not know how our
results would have changed if the relevant information
were available for all patients, but we believe that no
major systematic bias resulted from excluding patients
with missing information. Our data were based on infor-
mation documented in the hospital chart, which itself
reflects self-reported diagnosis and current medication
use, and this was not validated with the prescribing physi-
cian or the pharmacist. Patients may have over-reported
diagnosis, and their potential memory lapses could have
caused us to underestimate drug use. Nevertheless, such
limitations are not unique to our study and apply to any
investigation based on a retrospective review of hospital
charts, which itself remains a basic source for conducting
quality of care assessments of hospitalized patients.
Note that the ICONS study did collect data on comorbid-
ities as documented in the hospital record and, hence, a
cohort of "ideal" patients could have been constructed to
better reflect appropriateness of use for each drug class.
We chose not to do so for several reasons. First, given
generic problems with documentation in any medical
record, as already alluded to, there was no assurance that
construction of such "ideal" cohorts would have been
either accurate or comprehensive. Second, the present
report was intended to allow comparison of Nova Scotia
drug utilization rates with those published elsewhere,
especially from other jurisdictions in Canada, where over-
all or population-wide and not "ideal", rates were
reported. Third, we would propose that the absolute dif-
ference between the numbers of "ideal" patients and all
patients eligible for treatment is in fact small, at least from
the perspective of utilization rates of the four major drug
classes examined (antiplatelet agents, beta-blockers, ACE
inhibitors and statins).
Further to the issue of establishing appropriateness of
drug use, it is true that the elderly might have relatively
more comorbid conditions that, in some circumstances,
might relatively or even absolutely contraindicate the use
of certain medications. But most experts would agree that
elderly patients would nonetheless benefit from receiving
the drugs under examination, and the vast majority of
older patients should be able to tolerate them as well,
although some dose adjustment might be required.
Finally, one last limitation needs to be highlighted, espe-
cially as regards the use of ACE inhibitors. Because ICONS
was a population-based study of usual care, not all
patients underwent an objective assessment of their systo-
lic function. Thus, it is not possible to distinguish patients
with diastolic dysfunction from those with systolic or
mixed systolic and diastolic dysfunction. ACE inhibitors
are known to benefit patients with systolic dysfunction,
but no drug (including ACE inhibitors) has been defini-
tively shown to improve outcome in diastolic dysfunc-
tion. Having said that, during the time period under
review, there was a general consensus that patients with a
history of myocardial infarction stood to benefit from
treatment with an ACE inhibitor and, since the publica-
tion of the HOPE study [37], this benefit has extended to
patients with known or manifest coronary artery disease
of any kind. To the extent that this is the one drug class
wherein there existed, at least during the time interval
studied, comparatively greater discretion around use, the
relatively high levels of prescribing seen among primary
care physicians in Nova Scotia seems especially
exemplary.
Conclusions
We conclude that progress has been made in the imple-
mentation of evidence-based recommendations in cardio-
vascular care in ambulatory patients. However, the
absence of rigorously collected community family prac-
tice data on these issues is a glaring gap in our knowledge
of the care of these chronic diseases. For now, family phy-
sicians should ensure that all eligible patients with a prior
MI or a history of CHF are offered BBs or ACE inhibitors.
For patients with hyperlipidemia or hypertension, meet-
ing target levels for risk reduction should complement
continued attention to treating all eligible patients.
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